Piramal Pharma Ltd Q4 FY26 Earnings Analysis
Published 15 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹27.5K Cr
Price
₹207
Market Cap
₹27.5K Cr
Earnings Summary
FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
📊 Revenue & Sales Performance
- →FY27 revenue growth expected in the early to mid-teens percentage range across all businesses.
- →CDMO business growth anticipated to be healthy due to improved biotech funding, increased RFPs, higher win rates, and a strong pipeline of RFPs at overseas sites.
- →CDMO revenue will remain back-weighted to the second half, especially Q4, due to client order timings.
- →On-patent commercial manufacturing revenue grew nearly 50% from the prior year, with 15–16 products supplied; expected continued growth with new product launches.
- →ADC (Antibody-Drug Conjugates) segment poised to be a meaningful growth driver in FY27-FY28 and beyond with new customers added.
- →Consumer Health Care business grew 17% in FY26 and expects continued broad-based growth with premiumization and strategic launches.
- →API generics business expected to grow modestly, supported by new products and expanded market presence.
- →Overall, emphasis on sustainable, profitable growth with operating leverage expected to drive faster EBITDA growth than revenue.
📈 Profitability & Margins
- →For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
- →EBITDA and PAT are projected to grow faster than revenue in FY27.
- →The CDMO business will continue to be back-weighted to H2, particularly Q4, due to client delivery timings.
- →Operating margins are expected to improve as scale increases, with tax rates normalizing around 24-25%.
- →Long-term net debt-to-EBITDA target is approximately 1, though it remains elevated in the short term due to ongoing capital investments.
- →Growth drivers include expansion of overseas sites, differentiated specialty products, and momentum in consumer healthcare power brands and e-commerce.
- →Exceptional charges like intangible asset impairment in FY26 are not expected to recur regularly, with stricter capex prioritization in place.
- →Overall, management expresses confidence in returning to consistent and profitable growth in FY27 and beyond.
🏗️ Capital Expenditure Plans
- →The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
- →The Riverview expansion is largely complete and already serving clients.
- →Capex for FY27 is projected at INR 120 million to INR 135 million, largely towards the Lexington expansion.
- →No new significant capex plans were indicated beyond these projects, suggesting a period of consolidation.
- →Customer-funded capex related to a specific suite is complete; no further spend planned there.
- →Future capex excludes amounts spent on the Kenalog acquisition or potential similar deals.
- →The company is prioritizing capital allocation to areas with anticipated returns, reflected in a recent impairment of certain intangible assets.
💰 Fundraising & Capital Structure
- →There is no explicit mention of any new fundraising through debt or equity planned for FY27.
- →The company noted ongoing investments and capacity expansions are largely targeted and planned (e.g., Lexington expansion).
- →Debt level currently operates around a net debt-to-EBITDA ratio of 3.6x, expected to remain range-bound in FY27.
- →The company aims to reduce net debt-to-EBITDA to around 1x over the long term but expects elevated levels in the near term due to capex.
- →No mention of equity fundraising; capex for FY27 is estimated at INR 120-135 million, excluding acquisitions like Kenalog.
- →The company is managing working capital carefully to support cash flow and debt servicing.
- →Exceptional intangible asset impairment suggests prioritizing capital allocation but no direct references to raising funds.
📋 Order Book & Pipeline
- →Piramal Pharma is seeing a strong pipeline of Requests for Proposals (RFPs) at overseas sites, which, if converted, will help scale revenues and improve operating leverage.
- →The company has improved RFP-to-order conversion rates, especially with new customers.
- →A healthy order book for FY27 and beyond is expected, which is crucial for medium-term growth.
- →They are working on over 155 molecules in development, with 25 in Phase III, representing future on-patent commercial manufacturing opportunities.
- →CDMO business revenues were INR 1,708 crores in Q4 FY26 and INR 4,915 crores for the full year, with modest growth adjusted for temporary de-stocking.
- →Growth was slower in H1 due to subdued biopharma funding but rebounded strongly in H2, accelerating order inflows.
Key Metrics
Frequently Asked Questions
What were Piramal Pharma Ltd Q4 FY26 results?
FY27 revenue growth expected in the early to mid-teens percentage range across all businesses. For FY27, Piramal Pharma expects early to mid-teens revenue growth across all businesses.
What is Piramal Pharma Ltd share price analysis?
Piramal Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹27,530 Cr. Investors should review the full earnings analysis for detailed insights.
Is Piramal Pharma Ltd planning capital expenditure?
The Lexington expansion is ongoing with expected completion in the latter half of calendar year 2027.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.